GSK Bio
NEWS
Although there are many effective and safe COVID-19 vaccines around the world, the preferred vaccine is the Pfizer-BioNTech vaccine. For that and more stories, read on.
The scenery will continue to change for GlaxoSmithKline as the company’s planned demerger looms on the horizon. On Monday, GSK gave a glimpse of where the companies will call home post-split.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
GlaxoSmithKline shares jumped in aftermarket trading Wednesday after the WHO recommended broad deployment of the company’s malaria vaccine in sub-Saharan Africa and other areas.
With the planned departure from its 561,652-square-foot RTP campus, GSK will reduce its geographical footprint, but not its staff.
The deal’s termination was announced Thursday, months after bintrafusp alfa failed to hit the mark in a Phase II clinical trial as a potential second-line treatment for metastatic biliary tract cancer.
GlaxoSmithKline Chief Executive Officer Emma Walmsley faces renewed calls for her ouster after Bluebell Capital Partners has taken a £10 million (about $13.7 million) stake in the company.
CureVac NV is downsizing its European mRNA production network due to decreased demand for vaccines after the first wave of vaccinations.
AI can enable the analysis of massive databases, accelerate research and development, save costs and promote effective decision making.
JOBS
IN THE PRESS